Status:
COMPLETED
Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
Lead Sponsor:
University of Oklahoma
Conditions:
Atelectasis
Eligibility:
All Genders
18-90 years
Phase:
NA
Brief Summary
Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it is currently heavily used in this population. In fact, per evidence of barcode scanning via Meditech comput...
Eligibility Criteria
Inclusion
- Patient on invasive mechanical ventilation
- New Onset (\<48 hours) lobar or multilobar lung atelectasis based on CXR
Exclusion
- Asthma
- Severe COPD (FEV1\<30%)
- Pneumothorax or massive pleural effusion, thought to be causing the atelectasis
- Lobar atelectasis secondary to compressive tumor.
- Severe hypoxemia (PaO2/FiO2 \< 75)
- Hemodynamic Instability
- Cystic fibrosis patients
- Allergy to DNase
- Patients on Acetylcysteine
- Pregnant women
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2008
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT00671723
Start Date
October 1 2006
End Date
July 1 2008
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Presbyterian Hospital
Oklahoma City, Oklahoma, United States, 73104